... Abstract Neuroblastoma (NB) is the most common solid tumor in infancy. High-risk NB with an exceedingly high recurrence rate of 56% and a persistently dismal outcome of relapsed and refractory disease with an overall survival of below 20% despite high-dose chemotherapeutic regimens...

... ] were the first to report the use of ONS in 3 patients with persistent chronic occipital headache following Chiari decompression who were from a subset of 14 patients with different pain etiologies undergoing ONS. Current indications for ONS include refractory occipital neuralgia, chronic migraine...

... forpatients with hormone-refractory prostate cancer. Several new treatments are under investigationin phase III trials and will further improve the treatment options for these patients within the nextyears. ...

... structures affected. Radiotherapy for localized hormone-refractory prostate cancerhas an excellent local control rate; nevertheless, the prognosis is poor, the majority of patientsfailing with distant metastasis within few years. The role of radiotherapy in hormone-refractory andmetastatic prostate cancer...

... Abstract Refractory coeliac disease (RCD) is being currently definedas persisting or recurring villous atrophy with crypt hyperplasiaand increased intra-epithelial lymphocytes in spite ofa strict gluten-free diet for more than 12 months or whensevere persisting symptoms necessitate intervention...

... in the first half of the cycle, alternating every 2–3 weeks with ifosfamide, etoposide (VP-16) and high-dose methyl-prednisolone.All patients with HD had been pre-treated with both the MOPP and ABVD regimes. The median number of drugs given to patients with refractory NHL prior to induction with the BMV-VIP...

... Abstract SummaryThirty-five patients with refractory or recurrent non-Hodgkin’s lymphomas or Hodgkin’s disease were treated with a combination of VP-16, ifosfamide, and methotrexate with or without bleomycin (VIM(B)). An overall response rate of 83% was achieved including 34% complete responses...

... Abstract SummaryBetween 1977 and 1979 we carried out a Phase II trial of a four-drug combination (vincristine, BCNU, adriamycin, and prednisone [VBAP] ) for patients with refractory lymphoma. VBAP produced a 30 % response rate in 33 patients with diffuse non-Hodgkin's lymphoma (NHL) with a 4...